-
1
-
-
33748068118
-
Rates of diseases progression according to initial highly active antiretroviral therapy regimen: A collaborative analysis of 12 prospective cohort studies
-
The Antiretroviral Therapy Cohort Collaboration
-
The Antiretroviral Therapy Cohort Collaboration. Rates of diseases progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis. 2006;194:612-622.
-
(2006)
J Infect Dis
, vol.194
, pp. 612-622
-
-
-
2
-
-
0035857355
-
Virologic and regimen termination surrogate end points in AIDS clinical trials
-
Gilbert PB, DeGruttola V, Hammer SM, et al. Virologic and regimen termination surrogate end-points in AIDS clinical trials. JAMA. 2001; 285:777-784. (Pubitemid 32167237)
-
(2001)
Journal of the American Medical Association
, vol.285
, Issue.6
, pp. 777-784
-
-
Gilbert, P.B.1
DeGruttola, V.2
Hammer, S.M.3
Kuritzkes, D.R.4
-
3
-
-
0036972260
-
Analysis of virological efficacy in trials of antiretroviral regimens: Drawbacks of not including viral load measurements after premature discontinuation of therapy
-
Kirk O, Pedersen C, Law M, et al. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther. 2002;7:271-281. (Pubitemid 36427132)
-
(2002)
Antiviral Therapy
, vol.7
, Issue.4
, pp. 271-281
-
-
Kirk, O.1
Pedersen, C.2
Law, M.3
Gulick, R.M.4
Moyle, G.5
Montaner, J.6
Eron Jr., J.J.7
Phillips, A.N.8
Lundgren, J.D.9
-
4
-
-
52749083531
-
British HIV Association guidelines for the treatment of hIV-1-infected adults with antiretroviral therapy
-
on behalf of the BHIVA Treatment Guidelines Writing Group
-
Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of hIV-1-infected adults with antiretroviral therapy. HIV Med. 2008;9:563-608.
-
(2008)
HIV Med
, vol.9
, pp. 563-608
-
-
Gazzard, B.G.1
-
5
-
-
84855616052
-
-
Panel On Antiretroviral Guidelines For Adult And Adolescents Department of Health and Human Services Accessed May 2011
-
Panel on antiretroviral guidelines for adult and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2011:1-166. Available at: http//www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 2011.
-
(2011)
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
, pp. 1-166
-
-
-
6
-
-
77954692660
-
Antiretroviral treatment of adult HIV infection-2010. Recommendations of the IAS-USA panel
-
Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection-2010. Recommendations of the IAS-USA Panel. JAMA. 2010;304:321-333.
-
(2010)
JAMA
, vol.304
, pp. 321-333
-
-
Thompson, M.A.1
Aberg, J.A.2
Cahn, P.3
-
7
-
-
41649083599
-
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
-
DOI 10.1073/pnas.0800050105
-
Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA. 2008;105:3879-3884. (Pubitemid 351723493)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.10
, pp. 3879-3884
-
-
Palmer, S.1
Maldarelli, F.2
Wiegand, A.3
Bernstein, B.4
Hanna, G.J.5
Brun, S.C.6
Kempf, D.J.7
Mellors, J.W.8
Coffin, J.M.9
King, M.S.10
-
8
-
-
60049097896
-
Ultrasensitive assessment of residual HIV viremia in haart-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional study
-
Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV viremia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional study. J Med Virol. 2009;81:400-405.
-
(2009)
J Med Virol
, vol.81
, pp. 400-405
-
-
Bonora, S.1
Nicastri, E.2
Calcagno, A.3
-
9
-
-
79957608413
-
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of hiv-1 infected persons
-
Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2011;34:109-146.
-
(2011)
New Microbiol
, vol.34
, pp. 109-146
-
-
Antinori, A.1
Marcotullio, S.2
Ammassari, A.3
-
10
-
-
62749199717
-
Comparative evaluation of the VERSANT hiv-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of hiv-1 plasma viral load
-
Ruelle J, Jnaoui K, Lefevre I, et al. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol. 2009; 44:297-301.
-
(2009)
J Clin Virol
, vol.44
, pp. 297-301
-
-
Ruelle, J.1
Jnaoui, K.2
Lefevre, I.3
-
11
-
-
67949107943
-
Evaluation of the new VERSANT hiv-1 RNA 1.0 assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA
-
Troppan KT, Steltzl E, Violan D, et al. Evaluation of the new VERSANT HIV-1 RNA 1.0 assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J Clin Virol. 2009;46:69-74.
-
(2009)
J Clin Virol
, vol.46
, pp. 69-74
-
-
Troppan, K.T.1
Steltzl, E.2
Violan, D.3
-
12
-
-
2442670063
-
Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia
-
DOI 10.1016/j.jviromet.2004.02.015, PII S0166093404000655
-
Mackie N, Dustan S, McClure MO, et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viremia. J Virol Methods. 2004;119:73-78. (Pubitemid 38670397)
-
(2004)
Journal of Virological Methods
, vol.119
, Issue.2
, pp. 73-78
-
-
Mackie, N.1
Dustan, S.2
McClure, M.O.3
Weber, J.N.4
Clarke, J.R.5
-
13
-
-
84864287720
-
Rapid, robust and sustained antiviral response with once-daily dolutegravir, a next generation integrase inhibitor in combination therapy in antiretroviral-naïve adults: 48 week results from SPRING-1
-
July 17-20 Rome, Italy. Abstract TUAB01
-
Van Lunzen J, Maggiolo F, Phing B, et al. Rapid, robust and sustained antiviral response with once-daily dolutegravir, a next generation integrase inhibitor in combination therapy in antiretroviral-naïve adults: 48 week results from SPRING-1. Presented at: 6th IAS Conference; July 17-20, 2011; Rome, Italy. Abstract TUAB01.
-
(2011)
6th IAS Conference
-
-
Van Lunzen, J.1
Maggiolo, F.2
Phing, B.3
-
14
-
-
42549131481
-
+ cell counts and HIV RNA levels during follow-up
-
DOI 10.1086/529523
-
Lundgren JD, Babiker A, El Sadr WM, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral interruption strategy in the SMART study: role of CD4+ cell counts and HIV-RNA levels during follow-up. J Infect Dis. 2008;197:1145-1155. (Pubitemid 351590050)
-
(2008)
Journal of Infectious Diseases
, vol.197
, Issue.8
, pp. 1145-1155
-
-
Lundgren, J.D.1
Babiker, A.2
El-Sadr, W.3
Emery, S.4
Grund, B.5
Neaton, J.D.6
Neuhaus, J.7
Phillips, A.N.8
-
15
-
-
1842296349
-
+ lymphocytes as prognostic markers of HIV-1 infection
-
Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954. (Pubitemid 27255797)
-
(1997)
Annals of Internal Medicine
, vol.126
, Issue.12
, pp. 946-954
-
-
Mellors, J.W.1
Munoz, A.2
Giorgi, J.V.3
Margolick, J.B.4
Tassoni, C.J.5
Gupta, P.6
Kingsley, L.A.7
Todd, J.A.8
Saah, A.J.9
Detels, R.10
Phair, J.P.11
Rinaldo Jr., C.R.12
-
16
-
-
70349296826
-
Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant hiv-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiviral therapy
-
Shiu C, Cunningham CK, Greenough T, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiviral therapy. J Virol. 2009;83:9731-9742.
-
(2009)
J Virol
, vol.83
, pp. 9731-9742
-
-
Shiu, C.1
Cunningham, C.K.2
Greenough, T.3
-
17
-
-
42649135133
-
Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy
-
DOI 10.1097/QAI.0b013e31816a1d4f
-
Van Sighem A, Zhang S, Reiss P, et al. Immunologic, virologic and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2008; 48:104-108. (Pubitemid 351600855)
-
(2008)
Journal of Acquired Immune Deficiency Syndromes
, vol.48
, Issue.1
, pp. 104-108
-
-
Van Sighem, A.1
Zhang, S.2
Reiss, P.3
Gras, L.4
Van Der Ende, M.5
Kroon, F.6
Prins, J.7
De Wolf, F.8
-
18
-
-
0028874048
-
Rapid turnover of plasma virions and cd4 lymphocytes in hiv-1 infection
-
Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in hIV-1 infection. Nature. 1995;373:123-126.
-
(1995)
Nature
, vol.373
, pp. 123-126
-
-
Ho, D.D.1
Neumann, A.U.2
Perelson, A.S.3
-
19
-
-
0028811974
-
Viral dynamics in human immunodeficiency virus type 1 infection
-
Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
-
(1995)
Nature
, vol.373
, pp. 117-122
-
-
Wei, X.1
Ghosh, S.K.2
Taylor, M.E.3
-
20
-
-
0033520673
-
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
-
DOI 10.1001/jama.282.17.1627
-
Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632. (Pubitemid 29513968)
-
(1999)
Journal of the American Medical Association
, vol.282
, Issue.17
, pp. 1627-1632
-
-
Dornadula, G.1
Zhang, H.2
VanUitert, B.3
Stern, J.4
Livornese Jr., L.5
Ingerman, M.J.6
Witek, J.7
Kedanis, R.J.8
Natkin, J.9
DeSimone, J.10
Pomerantz, R.J.11
-
21
-
-
34548424552
-
+ T cell reservoir for HIV in patients on HAART
-
DOI 10.1371/journal.ppat.0030122
-
Sedaghat AR, Siliciano JD, Brennan TP, et al. Limits on replenishment of resting CD4+ T cell reservoir for HIV patients on HAART. PLoS Pathog. 2007;3:1165-1174. (Pubitemid 47359093)
-
(2007)
PLoS Pathogens
, vol.3
, Issue.8
, pp. 1165-1174
-
-
Sedaghat, A.R.1
Siliciano, J.D.2
Brennan, T.P.3
Wilke, C.O.4
Siliciano, R.F.5
-
22
-
-
39749112383
-
Low-level hiv-1 replication and the dynamics of the resting cd4+ T cell reservoir for hiv-1 in the setting of HAART
-
Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis. 2008;8:1-14.
-
(2008)
BMC Infect Dis
, vol.8
, pp. 1-14
-
-
Sedaghat, A.R.1
Siliciano, R.F.2
Wilke, C.O.3
-
23
-
-
0038579210
-
+ T cells
-
DOI 10.1038/nm880
-
Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727-728. (Pubitemid 36749221)
-
(2003)
Nature Medicine
, vol.9
, Issue.6
, pp. 727-728
-
-
Siliciano, J.D.1
Kajdas, J.2
Finzi, D.3
Quinn, T.C.4
Chadwick, K.5
Margolick, J.B.6
Kovacs, C.7
Gange, S.J.8
Siliciano, R.F.9
-
24
-
-
77950537810
-
Hiv-1 replication and immune dynamics are affected by raltegravir intensification of haart-suppressed subjects
-
Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460-465.
-
(2010)
Nat Med
, vol.16
, pp. 460-465
-
-
Buzon, M.J.1
Massanella, M.2
Llibre, J.M.3
-
25
-
-
77949592502
-
Antiretroviral intensification and valproic acid lack sustained effect on residual hiv-1 viremia or resting cd4+ cell infection
-
Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010;5:1-4.
-
(2010)
PLoS One
, vol.5
, pp. 1-4
-
-
Archin, N.M.1
Cheema, M.2
Parker, D.3
-
26
-
-
77749277080
-
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with hiv-1 suppression during receipt of combination antiretroviral therapy
-
McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912-919.
-
(2010)
Clin Infect Dis
, vol.50
, pp. 912-919
-
-
McMahon, D.1
Jones, J.2
Wiegand, A.3
-
27
-
-
78751616765
-
The significance of very lowlevel viremia detected by sensitive viral load assays in HIV infected patients on HAART
-
Widdrington J, Payne B, Medhi M, et al. The significance of very lowlevel viremia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect. 2011;62:87-92.
-
(2011)
J Infect
, vol.62
, pp. 87-92
-
-
Widdrington, J.1
Payne, B.2
Medhi, M.3
-
28
-
-
84863115427
-
Plasma hiv-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy
-
Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54:729-737.
-
(2012)
Clin Infect Dis
, vol.54
, pp. 729-737
-
-
Doyle, T.1
Smith, C.2
Vitiello, P.3
-
29
-
-
84859178656
-
Residual viremia does not influence 1 year virological rebound in hiv-infected patients with hiv-rna persistently below 50 copies/ml
-
Gianotti N, Galli L, Racca S, et al. Residual viremia does not influence 1 year virological rebound in HIV-infected patients with HIV-rna persistently below 50 copies/ml. J Antimicrob Chemother. 2012;67:213-217.
-
(2012)
J Antimicrob Chemother
, vol.67
, pp. 213-217
-
-
Gianotti, N.1
Galli, L.2
Racca, S.3
-
30
-
-
78650230394
-
Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level
-
Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55:460-465.
-
(2010)
J Acquir Immune Defic Syndr
, vol.55
, pp. 460-465
-
-
Lima, V.D.1
Bangsberg, D.R.2
Harrigan, P.R.3
-
31
-
-
84856896754
-
Plasma hiv-1 RNA levels during antiretroviral therapy: How low is low enough?
-
Gandhi RT, Deeks SG. Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough? Clin Infect Dis. 2012;54:1-3.
-
(2012)
Clin Infect Dis
, vol.54
, pp. 1-3
-
-
Gandhi, R.T.1
Deeks, S.G.2
-
32
-
-
56749149574
-
Determinants of virologic failure after successful viral load suppression in first-line highly active antiretroviral therapy
-
Geretti AM, Smith C, Haberl A, et al. Determinants of virologic failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13:927-936.
-
(2008)
Antivir Ther
, vol.13
, pp. 927-936
-
-
Geretti, A.M.1
Smith, C.2
Haberl, A.3
-
33
-
-
47749112849
-
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400-HIV-RNA cp/ml) during different antiretroviral regimes
-
DOI 10.2174/157016208784325010
-
Nicastri E, Palmisano L, Sarmati L, et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (,400 HIVRNA cp/ml) during different antiretroviral regimens. Curr HIV Res. 2008;6:261-266. (Pubitemid 352024679)
-
(2008)
Current HIV Research
, vol.6
, Issue.3
, pp. 261-266
-
-
Nicastri, E.1
Palmisano, L.2
Sarmati, L.3
D'Ettorre, G.4
Parisi, S.5
Andreotti, M.6
Buonomini, A.7
Pirillo, F.M.8
Narciso, P.9
Bellagamba, R.10
Vullo, V.11
Montano, M.12
Di Perri, G.13
Andreoni, M.14
-
34
-
-
0036749951
-
Simpler regimens may enhance adherence to antiretroviral in HIV-infected patients
-
Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV infected patients. HIV Clin Trials. 2002;5:371-378. (Pubitemid 35189880)
-
(2002)
HIV Clinical Trials
, vol.3
, Issue.5
, pp. 371-378
-
-
Maggiolo, F.1
Ripamonti, D.2
Arici, C.3
Gregis, G.4
Quinzan, G.5
Camacho, G.A.6
Ravasio, L.7
Suter, F.8
-
35
-
-
34047198735
-
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-Week results of the five-days-on, two-days-off (FOTO) study
-
DOI 10.1310/hct0801-19
-
Cohen CJ, Colson AE, Sheble-Hall AG, et al. Pilot study of a novel shortcycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. Antivir Ther. 2010;8:19-23. (Pubitemid 46542906)
-
(2007)
HIV Clinical Trials
, vol.8
, Issue.1
, pp. 19-23
-
-
Cohen, C.J.1
Colson, A.E.2
Sheble-Hall, A.G.3
McLaughlin, K.A.4
Morse, G.D.5
-
36
-
-
79960443775
-
Detection of drug resistance mutations at low plasma hiv-1 RNA load in a european multicenter cohort study
-
Prosperi MCF, Mackie N, Di Giambenedetto S, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicenter cohort study. J Antimicrob Chemother. 2011;66:1886-1896.
-
(2011)
J Antimicrob Chemother
, vol.66
, pp. 1886-1896
-
-
Prosperi, M.C.F.1
MacKie, N.2
Di Giambenedetto, S.3
-
37
-
-
77950923702
-
Antiretroviral drug resistance in hiv-1-infected patients with low-level viremia
-
Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010;201:1303-1307.
-
(2010)
J Infect Dis
, vol.201
, pp. 1303-1307
-
-
Mackie, N.E.1
Phillips, A.N.2
Kaye, S.3
-
38
-
-
4744362201
-
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy
-
DOI 10.1086/423388
-
Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39: 1030-1037. (Pubitemid 39313462)
-
(2004)
Clinical Infectious Diseases
, vol.39
, Issue.7
, pp. 1030-1037
-
-
Nettles, R.E.1
Kieffer, T.L.2
Simmons, R.P.3
Cofrancesco Jr., J.4
Moore, R.D.5
Gallant, J.E.6
Persaud, D.7
Siliciano, R.F.8
-
39
-
-
12344313124
-
Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy
-
DOI 10.1086/427340
-
Ostrowski SR, Katzenstein TL, Thim PT, et al. Low-level viremia and proviral DNA impede immune reconstruction in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191: 348-357. (Pubitemid 40139759)
-
(2005)
Journal of Infectious Diseases
, vol.191
, Issue.3
, pp. 348-357
-
-
Ostrowski, S.R.1
Katzenstein, T.L.2
Thim, P.T.3
Pedersen, B.K.4
Gerstoft, J.5
Ullum, H.6
|